Oncolytics Biotech Inc T.ONC

Sanofi's M&A plans of insulin company hit by FTC delay

[Noteable]

April 11, 2023 -  Sanofi had to withdraw and refile its proposal to acquire Provention Bio to give the Federal Trade Commission more time to complete its review. The centerpiece of the deal, Tzield, is the first and only FDA-approved treatment to delay the onset of Type 1 diabetes. The acquisition builds on a previous co-promotion pact, under which Sanofi lended its commercialization clout.

https://www.fiercepharma.com/pharma/sanofis-29b-deal-provention-bio-hit-protracted-ftc-review-wheres-pfizer-seagen

[Noteable]

"As Sanofi works through the FTC delay, all eyes in biopharma are focused on how the agency will rule on another deal: Pfizer’s proposed $43 billion acquisition of cancer drug developer Seagen. Thanks to an FDA approval in 2020, Bavencio became a standard of care as a front-line maintenance treatment for bladder cancer patients who’ve responded to a round of chemotherapy. Then

[Noteable]

With Pfizer's US$43 Billion acquisition plans of Seagen in the hands of the Federal Trade Commission, who are experiencing capacity issues and increasing review delays, Pfizer's original plans to complete their acquisition of Seagen by Q4 2023 or Q1 2024, may in fact now be delayed until Q2/Q3 2024.  As Pfizer begins to process the general delays the FTC is experiencing, since the

[m00nsh0ts]

What about another posters comment that since Pfizer gave up Bavencio they would have to start from scratch with another ICI and indeed, would be starting over with a subcutaneous version.

[Noteable]

Whichever Big Pharma company that acquires ONCY's pelareorep, once pelareorep receives approval for one indication, in either breast or pancreatic cancer for example, that Big Pharma company will take whatever time it needs to obtain additional approvals with other I/O agents including subcutaneous PD-1 immune checkpoint inhibitors like Pfizer's sasanlimab, and in the process will be